Vaxcyte (PCVX) Statistics

Vaxcyte, Inc. (PCVX) is a biotechnology company focused on the development and commercialization of vaccines to prevent serious infectious diseases. The company's lead product candidate is VAX-24, a protein-based pneumococcal conjugate vaccine (PCV) designed to provide broad protection against pneumococcal disease. PCVX stock statistics show that the company has a market capitalization of approximately $2.5 billion and its stock is traded on the Nasdaq Global Select Market. As of the latest available data, the stock has a 52-week high of $45.82 and a 52-week low of $13.71. The stock has shown significant volatility, with an average daily trading volume of over 1 million shares.

In terms of valuation metrics, Vaxcyte, Inc. (PCVX) has a price-to-earnings ratio (P/E) of 27.52 and a price-to-sales ratio (P/S) of 25.37. These metrics suggest that the stock may be relatively expensive compared to its earnings and sales. However, it's important to note that the company is still in the early stages of commercialization and has significant potential for future growth. The company's fundamentals also look promising, with a strong financial position and a solid pipeline of vaccine candidates. Vaxcyte, Inc. has reported revenue per share of $0.41, indicating that the company generates revenue from the sale of its vaccines. The company's enterprise to EBITDA ratio is 39.75, suggesting that it has a relatively low level of debt and is able to generate strong earnings. The company's profit margin is not currently available, as it is a development-stage company and has not yet reached profitability. As of the latest available data, Vaxcyte, Inc. has total debt of $35 million. The company's gross profit is also not currently available, as it is a development-stage company and has not yet generated significant revenues. The CEO of Vaxcyte, Inc. is Grant Pickering, who has a strong background in the biotechnology industry and is leading the company's efforts to bring innovative vaccines to market.